IL10 and cancer: The immunostimulatory functions of the PEGylated form of IL-10 (pegilodecakin), that extend the cytokine lifetime, were confirmed in cancer patients [226], but it did not improve the outcome of patients with gemcitabine-refractory metastatic pancreatic [227] or metastatic lung cancer [228].